1stOncology™: Cancer Intelligence Service – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Molecular Partners to Present at Inaugural UBS Global Biopharma Conference

On November 13, 2026 Molecular Partners AG (SIX, NASDAQ: MOLN), a clinical-stage biotech company developing a novel class of medicines known as DARPin therapeutics ("Molecular Partners" or the "Company"), reported it will present the Company’s latest developments and outlook at the Inaugural UBS Biopharma Conference, taking place 16–17 November 2026 in London, United Kingdom.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

Chief Executive Officer Patrick Amstutz will present on Tuesday, November 17 at 8am GMT (9am CET) at the Rosewood Hotel in London.

A webcast will be accessible on the Molecular Partners website, under the Events tab.

(Press release, Molecular Partners, NOV 13, 2026, View Source [SID1234674775])

Pasithea Therapeutics Presents Positive Initial Phase 1/1b Data for PAS-004, Showing Substantial Reductions in Cutaneous Neurofibroma Size and Early Activity in Plexiform Neurofibromas at the 2026 European Neurofibromatosis Conference

On November 13, 2026 Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor, reported positive clinical data from its ongoing Phase 1/1b study in adults with neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) and a subset of patients with cutaneous neurofibromas (cNF) (Study PAS-004-103, NCT06961565), presented at the 2026 European Neurofibromatosis Conference in Vienna, Austria.

"Cutaneous neurofibromas do not regress spontaneously and generally increase in number and size with age. The substantial reductions in cNF size reported today represent an encouraging clinical signal in a condition for which there are currently no FDA-approved systemic treatments," said Dr. Tiago Reis Marques, Chief Executive Officer of Pasithea. "Importantly, these reductions have continued to deepen with longer treatment, including at the lowest doses tested. With our IND now cleared by FDA’s Division of Dermatology and Dentistry, these findings reinforce our confidence in the 4mg to 12mg dose range planned for Phase 2 and support advancing PAS-004 into a randomized, placebo-controlled study in cNF."

"The reductions in cNF size observed with oral PAS-004 highlight its potential to provide broad, visible improvements for patients through a systemic treatment approach, rather than relying on local procedures that can treat individual lesions," said Dr. Kartik Krishnan, Chief Medical Officer of Pasithea. "We are also seeing early activity in plexiform neurofibromas, with reductions in tumor volume across all dose levels and two participants meeting the REiNS threshold for partial response, including one at the first on-treatment MRI. Together with the favorable tolerability observed to date and a pharmacokinetic profile characterized by a 40-to-60-hour half-life and limited peak-to-trough fluctuations, these findings support the continued development of PAS-004 as a once-daily oral therapy for long-term treatment of NF1-associated neurofibromas."

Pasithea will post a webcast on Friday, November 13, 2026, at 7:00 a.m. EST to discuss the PAS-004 clinical data presented at the 2026 European Neurofibromatosis Conference. The webcast will be accessible here and through the Investors section of the Company’s website.

Study Overview

Study PAS-004-103 is an ongoing multicenter, open-label Phase 1/1b trial in adults with NF1 and symptomatic and inoperable, incompletely resected, or recurrent PN at five sites in the United States, Australia and South Korea. The study also evaluates up to 7 cNFs in participants with measurable lesions. Part A studies six escalating doses using a 3+3 design to select two doses for evaluation in Part B, a randomized dose expansion phase. The study also assesses safety, tolerability, pharmacokinetics and pharmacodynamics.

As of September 15, 2026, 19 participants have been enrolled across six cohorts (4, 8, 12, 15, 18 and 24mg). Of these, 15 were evaluable for cNF and 18 for PN response. Median treatment duration ranged from 14.4 months at 4mg to approximately 4 months at 15mg and 24mg. One participant discontinued by sponsor decision for noncompliance, unrelated to safety.

Cutaneous Neurofibroma (cNF) Data

Fifteen participants were evaluable for cNF, with 71 target cNFs measured at baseline. Length and width of each target cNF were measured in triplicate with digital calipers. As there is no regulatory standard for assessing cNFs, both surface area (calculated from length and width) and longest diameter (the REiNS-recommended caliper measure) are reported.

Substantial Reductions in cNF Surface Area (Figure 1)

Reductions Across All Doses: All 15 evaluable participants showed reductions in summed target cNF surface area at best response, with a median best reduction of 41%.

Activity at Planned Phase 2 Doses: Among eight evaluable participants treated at 4, 8 and 12mg, the median best reduction was 46%. All six participants treated at 4mg and 8mg achieved reductions greater than 40%.

Safety and Tolerability

No treatment-related serious adverse events, discontinuations, adverse events of decreased LVEF, or cases of retinopathy have been reported. Most treatment-related adverse events were Grade 1 or 2 (97.6% of events). The two Grade 3 treatment-related events were asymptomatic increases in blood creatine phosphokinase (CPK), both of which resolved following a one-week dose interruption, with both participants continuing treatment. At the 4 to 12mg doses planned for Phase 2, dermatitis acneiform (rash) and diarrhea occurred in 33% and 11% of participants, respectively (data cut-off: September 15, 2026).

Pharmacokinetics

PAS-004 showed approximately dose-proportional exposure across the 4 to 24mg range, a terminal half-life of 40 to 60 hours, and limited peak-to-trough fluctuations (Cmax/Cmin of 1.5 to 2.0), consistent with findings from the Company’s ongoing Phase 1 study in advanced solid tumors and supporting once-daily dosing (data cut-off: October 7, 2026).

Next Steps

The FDA’s Division of Dermatology and Dentistry has cleared the IND for Study PAS-004-201, a randomized, double-blind, placebo-controlled Phase 2 trial evaluating three once-daily doses of PAS-004 in approximately 200 adults with NF1-associated cNF.

The ongoing Phase 1/1b study (PAS-004-103) will continue participant follow-up and advance toward Part B, a randomized two-dose expansion phase. The Company expects to complete pharmacodynamic analyses of resected cNFs in 2027 and present additional clinical data at future scientific meetings.

About Cutaneous Neurofibromas (cNF)

NF1-associated cutaneous neurofibromas (cNFs) are benign tumors that grow in or just beneath the skin at virtually any location in the body and are a hallmark of NF1. It is a serious condition and cNFs are associated with significant morbidity that can have substantial impact on day-to-day functioning, leading patients to rate this as the most significant burden of NF1 despite other potentially life-threatening complications. cNF typically begin to appear in adolescence, generally increase in number and volume with age. The number of cNFs on an individual patient can range from a few to thousands. Although malignant transformation does not occur with NF1-associated cNF, cNFs are present in over 95% of individuals with NF1 and have a significant negative impact both physically, with disfigurement, and on health-related quality of life. Current management relies largely on procedural approaches such as surgical excision, electrodesiccation, or laser therapy. There are no FDA-approved systemic therapies for the treatment of NF1-associated cNF.

About Plexiform Neurofibromas (PN)

NF1-associated plexiform neurofibromas (PNs) are tumors originating from the nerve sheath that grow through and around nerves and may involve multiple nerve branches. Thirty to fifty percent (30-50%) of patients with NF1 will harbor PNs, which can undergo malignant transformation. PN-related morbidities, including pain, disfigurement and functional impairment are primarily caused by the direct impact of the tumor on surrounding structures and can be life-threatening when they compress vital organs or when they become malignant.

(Press release, Pasithea Therapeutics, NOV 13, 2026, View Source [SID1234674774])

Tvardi Therapeutics Announces Third Quarter 2026 Results and Provides Business Update

On November 13, 2026 Tvardi Therapeutics, Inc. ("Tvardi" or the "Company") (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, reported its ﬁnancial and operating results for the third quarter ended September 30, 2026, and provided a business update.

Business and Clinical Program Updates:

TTI-109 – Ulcerative Colitis (UC)

Advancing development plans for TTI-109 in UC. Building on positive Phase 1 healthy volunteer results reported in July and the subsequent selection of UC as its initial target indication, Tvardi is preparing to advance TTI-109 into clinical development in UC, subject to clearance of our Investigational New Drug (IND) application and additional funding.
The Phase 1 results confirmed the prodrug design, with TTI-109 delivering TTI-101-equivalent exposure with improved tolerability and, across the active dose range, demonstrated reductions in cellular and humoral immune populations known to correlate with UC disease severity, providing pharmacodynamic evidence of STAT3 target engagement.
Published additional preclinical data supporting STAT3 inhibition in UC. New findings published in the International Journal of Molecular Sciences demonstrated that, in a preclinical model of chronic colitis, TTI-101 achieved colon tissue exposure approximately eightfold higher than in plasma, normalized disease-associated changes in colon gene expression, muted colitis-associated changes in the gut microbiome and prevented the formation of colon adenocarcinomas, a long-term consequence of chronic colitis.
The preclinical data highlights the potential of STAT3 inhibition to address immune dysregulation, inflammation and fibrosis that drive UC progression. These findings build on prior preclinical studies in which TTI-101 and TTI-109 significantly reduced disease activity across three acute colitis models representing distinct immune axes.

TTI-101 – Hepatocellular Carcinoma (HCC)

Advancing Phase 1b/2 REVERT LIVER CANCER study toward topline readout in early first quarter of 2027. The ongoing REVERT LIVER CANCER study is evaluating TTI-101 as monotherapy and in combination with established therapies in patients with HCC. The Company expects to report topline data early in the first quarter of 2027 to allow for complete cohort evaluation.

Imran Alibhai, Ph.D., Chief Executive Officer of Tvardi, stated, "We continue to make meaningful progress across our pipeline. Positive Phase 1 results for TTI-109 have strengthened our confidence in its potential as we prepare to advance this next-generation STAT3 inhibitor into clinical development in ulcerative colitis and potentially other inflammatory bowel diseases in 2027, subject to the availability of additional funding. In HCC, we remain encouraged by the previously reported interim results for TTI-101 and look forward to the topline readout in early first quarter of 2027, which will help inform our next steps."

Key Upcoming Milestones

2027: Initiation of clinical trial of TTI-109 in UC, subject to IND clearance and additional funding
Early first quarter of 2027: TTI-101 Phase 1b/2 HCC topline data

Third Quarter 2026 Financial Results

Research and development expenses for the three months ended September 30, 2026, were $4.5 million, compared to $3.6 million for the comparable period in 2025. The increase was primarily driven by higher clinical costs associated with TTI-101.

General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $2.3 million for the three months ended September 30, 2025. The decrease was primarily driven by lower professional fees.

Net loss for the three months ended September 30, 2026, was $6.1 million, compared to a net loss of $5.5 million for the three months ended September 30, 2025.

Basic and diluted net loss per share attributable to common stockholders for the three months ended September 30, 2026, were both $(0.48), compared to basic and diluted net loss per share of $(0.59) for the three months ended September 30, 2025.

Cash and cash equivalents as of September 30, 2026, were $22.3 million, compared to cash, cash equivalents and short-term investments of $30.8 million as of December 31, 2025. Tvardi anticipates that its existing cash and cash equivalents will be sufficient to fund operations, as currently planned, into the third quarter of 2027. Advancing TTI-109 into UC and additional indications remain subject to additional funding and IND clearance.

(Press release, Tvardi Therapeutics, NOV 13, 2026, View Source [SID1234674773])

Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth

On November 13, 2026 Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a biopharmaceutical company specializing in the development and commercialization of photodynamic therapy (PDT) in dermatology, reported financial results for the quarter ended September 30, 2026.

Third Quarter 2026 Highlights

Net product revenue of $9.1 million, an increase of 29.8% compared to $7.0 million in the prior-year period.
Gross margin of 74.4%, compared to 70.7% in the prior-year period, an improvement of approximately 370 basis points, reflecting the lower Ameluz cost structure established following the closing of the strategic transaction with Biofrontera AG in October 2025 (the "Strategic Transaction"), partially offset by ITC Matter-related inventory write-downs and higher lamp and device costs.
Net loss of $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62) per share, in the prior-year period.
Adjusted EBITDA of $(5.5) million, compared to $(6.0) million in the prior-year period.
On September 9, 2026 FDA Approval of Ameluz on September for the treatment of Superficial Basal Cell Carcinoma (sBCC), making Ameluz plus Red-Light the first and only PDT approved for the treatment of cancerous skin tumors.
US Customs and Border Protection ruled that the re-designed XL-C lamp did not violate the ITC order and could be imported for use in the US market.

Nine Months Ended September 30, 2026 Highlights

Net product revenue of $31.2 million, an increase of 26.6% from $24.6 million in the prior-year period.
Gross margin of 78.0%, compared to 67.7% in the prior-year period.
Net loss of $11.8 million, or $(0.89) per share, compared to a net loss of $16.2 million, or $(1.67) per share, in the prior-year period.
Adjusted EBITDA of $(9.3) million, compared to $(15.5) million in the prior-year period.

Hermann Luebbert, Chief Executive Officer and Chairman of Biofrontera, stated: "The third quarter was a pivotal one for Biofrontera. On September 9, the FDA approved Ameluz PDT for the treatment of superficial basal cell carcinoma (sBCC), making it the first PDT approved in the United States for a cancerous skin tumor. Five days later, U.S. Customs and Border Protection ruled that our redesigned RhodoLED XL-C is not subject to the ITC exclusion order, which allows us to again serve the customers who rely on our large-field lamp. Revenue grew 30% in the quarter and 27% for the first nine months, and our gross margin continues to reflect the lower cost structure we put in place with the Strategic Transaction. The quarter also carried the legal and remediation costs of the ITC Matter, and with the XL-C now cleared our attention is on execution. We are preparing to begin commercializing Ameluz for sBCC later in the fourth quarter and into the first quarter of 2027, and in October we submitted a supplemental New Drug Application to expand the Ameluz label for actinic keratosis to the extremities, neck and trunk. Each of these indications is served by the lamps and the sales force we already have in place."

Third Quarter 2026 Financial Results

Net product revenue for the third quarter of 2026 was $9.1 million, an increase of $2.1 million, or 29.8%, from $7.0 million in the third quarter of 2025. The increase was primarily attributable to a 23.3% increase in Ameluz unit volume resulting in an increase of $1.6 million and $0.3 million due to price and mix increase, with the balance reflecting higher device sales. The increase in unit volume was partially driven by accelerated order timing from certain customers in early July 2026 in anticipation of potential supply restrictions resulting from the limited exclusion order and cease and desist order issued by the U.S. International Trade Commission ("ITC") related to our RhodoLED XL lamp, which took effect on July 6, 2026 (the "ITC Matter") and importantly, commercial execution where we have focused on increasing utilization with key accounts and bringing Ameluz to new dermatology customers. We believe that the accelerated ordering impacted the timing of orders rather than total demand. On September 14, 2026, U.S. Customs and Border Protection ("CBP") issued a ruling finding that our redesigned RhodoLED XL-C is not subject to the exclusion order, and we began placing XL-C lamps during the 3rd quarter, enabling these customers to again purchase Ameluz.

Cost of revenues was $2.3 million, compared to $2.0 million in the prior-year period, producing gross profit of $6.7 million and a gross margin of 74.4%, compared to gross profit of $4.9 million and a gross margin of 70.7% in the third quarter of 2025. The improvement was driven principally by the transition from the prior transfer pricing arrangement to a cost structure comprising Ameluz direct cost plus a 12% earnout on net revenue, which reduced cost of Ameluz despite a 23.3% increase in unit volume. This was partially offset by a $0.4 million increase in lamp and device costs, including $0.3 million of ITC Matter-related inventory write-downs.

Selling, general and administrative ("SG&A") expenses, including SG&A, related party, were $12.5 million, compared to $10.4 million in the prior-year quarter, an increase of $2.1 million, driven primarily by a $0.9 million increase in legal fees related to the ITC Matter, $0.7 million of combined costs from lamp manufacturing and regulatory and product affairs, and a $0.5 million increase in direct sales expenses, mainly commissions on higher Ameluz sales volume.

Research and development expenses were $0.5 million, compared to $0.9 million in the prior-year quarter, reflecting the substantial completion of clinical trials.

Patent remediation expense related to the ITC Matter was $0.3 million, compared to none in the prior-year quarter, reflecting a $0.2 million increase in the estimated remediation cost following the September 14, 2026 CBP ruling and a $0.1 million write-down of loaner and RhodoLED XL lamps used in the remediation program.

Net loss for the third quarter was $6.4 million, or $(0.42) per share, compared to a net loss of $6.6 million, or $(0.62) per share, for the prior-year quarter. Adjusted EBITDA, a non-GAAP measure reconciled below, was $(5.5) million, compared to $(6.0) million in the prior-year period.

Nine Months Ended September 30, 2026 Financial Results

Net product revenue for the nine months ended September 30, 2026 was $31.2 million, an increase of $6.6 million, or 26.6%, from $24.6 million in the first nine months of 2025. The increase reflects Ameluz unit volume growth of $5.5 million and a price impact of approximately $0.7 million and the remainder generally attributable to increases in device sales.

Cost of revenues was $6.8 million, compared to $8.0 million in the prior-year period, producing gross profit of $24.3 million and gross margin of 78.0%, compared to gross profit of $16.7 million and gross margin of 67.7% in the prior-year period. The improvement was driven principally by the same transition in Ameluz cost structure described above.

SG&A expenses, including SG&A related party, were $33.2 million, compared to $29.6 million in the prior-year period, an increase of $3.5 million. The increase was primarily driven by $1.8 million of combined costs from manufacturing and regulatory and product affairs; $1.2 million of higher direct sales expenses, mainly sales commissions reflecting Ameluz sales volume growth; and $0.8 million of higher sales support expenses, reflecting increased commercial activity. Other SG&A expenses, including stock-based compensation, depreciation and amortization, and bad debt, increased $0.3 million. These increases were partially offset by a $0.3 million decrease in selling, general and administrative expenses, related party, and a $0.2 million decrease in general and administrative costs.

Research and development expenses were $1.8 million, compared to $2.9 million, reflecting the substantial completion of clinical trials.

Patent remediation expense related to the ITC Matter was $0.7 million, compared to none in the prior-year period. Including inventory write-downs recorded in cost of revenues, the Company has recognized total charges of $1.1 million related to the ITC Matter through September 30, 2026, consisting of $0.6 million of accrued remediation costs and $0.5 million of inventory write-downs to net realizable value. Of the accrued remediation costs, $0.2 million was settled with inventory used in the remediation program and the remaining $0.4 million is paid or payable in cash.

Net loss was $11.8 million, or $(0.89) per share, compared to a net loss of $16.2 million, or $(1.67) per share, in the prior-year period. Adjusted EBITDA was $(9.3) million, compared to $(15.5) million in the prior-year period.

Please refer to the table below which presents a GAAP to non-GAAP reconciliation of Adjusted EBITDA for the third quarters and first nine months of 2026 and 2025.

Balance Sheet and Cash Flow

Cash and cash equivalents were $3.2 million as of September 30, 2026, compared to $6.4 million as of December 31, 2025. Cash used in operating activities for the nine months ended September 30, 2026 was $3.2 million, compared to $11.0 million in the prior-year period.

Total liabilities were $21.7 million as of September 30, 2026, compared to $18.1 million at December 31, 2025. The Company’s outstanding indebtedness as of September 30, 2026 consisted of $4.7 million of convertible notes, net, maturing in November 2027. The Company has no bank or other term debt.

Conference Call

Biofrontera will host a conference call and webcast on Friday, November 13, 2026 at 10:00 a.m., Eastern Time. Participants may dial 1-877-877-1275 (U.S./Canada toll-free), 1-866-605-3852 (Canada toll-free), or 1-412-858-5202 (international).

(Press release, Biofrontera, NOV 13, 2026, View Source [SID1234674772])

Allarity Therapeutics Reports Third Quarter 2026 Results and Provides Full Year 2026 Financial Guidance

On November 13, 2026 Allarity Therapeutics, Inc. ("Allarity" or the "Company") (NASDAQ: ALLR), a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib (2X-121)—a differentiated, dual PARP and WNT pathway inhibitor, reported financial results for the third quarter ended September 30, 2026, and provided an update on its clinical and business activities.

Third Quarter 2026 Financial Highlights

Cash Position: As of September 30, 2026, Allarity had $24.1 million in cash and restricted cash, including $10.0 million in restricted cash.
R&D Expenses: Research and Development expenses were $4.2 million, compared with $1.2 million in the third quarter of 2025. The increase primarily reflected a $3.2 million charge for manufacturing stenoparib active pharmaceutical ingredient (API) to support drug supply for a potential Phase 3 trial.
G&A Expenses: General and administrative expenses for the third quarter of 2026 were $1.3 million, unchanged from $1.3 million for the third quarter of 2025.
Net Loss: Net loss attributable to common stockholders for the third quarter of 2026 was $6.2 million, compared to $2.8 million for the third quarter of 2025. A $3.2 million one-time manufacturing expense accounted for most of the year-over-year increase.
Fourth Quarter and Full Year 2026 Guidance

Liability Settlement Agreement: Subsequent to quarter-end, Allarity entered into a Settlement and Release Agreement with Novartis Pharma AG relating to liabilities arising from the previously terminated dovitinib license agreement. Under the agreement, Allarity paid $1.0 million in full settlement of an aggregate liability of $4.9 million, plus accrued interest.
Fourth Quarter and Full Year 2026 Guidance: Allarity is providing guidance for earnings of $0.01 to $0.04 per share in the fourth quarter. The one-time extraordinary gain from extinguishment of debt is expected to exceed operating expenses for the quarter. Allarity anticipates a full year 2026 loss between $0.73 and $0.76 per share. These figures are preliminary and unaudited, and actual results may differ from these estimates. The Company is not providing financial guidance for 2027.
"Completing API manufacturing gives us a head start on drug supply for a potential Phase 3 trial of stenoparib in advanced ovarian cancer while enrollment continues in our Phase 2 studies," said Thomas Jensen, Chief Executive Officer of Allarity. "We resolved a significant legacy liability and the expected gain from that settlement is the primary driver of our fourth-quarter earnings guidance. Our first contract under the CLIA laboratory services strategy is an early step toward generating revenue from capabilities we built for our own development programs. We’re also strengthening the intellectual property behind those programs, with a newly granted Japanese patent that protects our stenoparib DRP companion diagnostic into 2039."

Clinical and Drug Development Progress

Phase 2 Ovarian Cancer Program: Enrollment continued in the Phase 2 trial evaluating stenoparib in advanced, recurrent, platinum-resistant or platinum-ineligible ovarian cancer under U.S. Food and Drug Administration (FDA) Fast Track designation.
VA-funded Phase 2 Combination Trial: In parallel, the study evaluating stenoparib in combination with temozolomide for relapsed small cell lung cancer continued to enroll patients across multiple U.S. Department of Veterans Affairs (VA) medical centers. The combination trial is fully funded by the VA.
Japanese Patent for the Stenoparib DRP Companion Diagnostic: In September, the Japan Patent Office granted a patent for the stenoparib DRP companion diagnostic, providing protection into 2039. The patent further strengthens the intellectual property supporting stenoparib development with its drug-specific DRP companion diagnostic.

Corporate and Strategic Developments

CLIA Certification: In July, Allarity announced that its laboratory in Hoersholm, Denmark, had obtained a Certificate of Registration under the Clinical Laboratory Improvement Amendments (CLIA). The certification supports in-house DRP testing for U.S. clinical trials, including a potential registrational stenoparib trial in advanced ovarian cancer, and enables Allarity to offer laboratory services to other biotechnology and pharmaceutical companies.
First Contract Under the CLIA Laboratory Services Strategy: Subsequent to quarter-end, in October, Allarity announced its first revenue-generating contract under its newly established CLIA-certified laboratory services strategy. Under the agreement, the Company will provide a European biotechnology company with development, validation and related laboratory services to support implementation of a proprietary precision oncology predictive device for use in the United States.
Expanded Research Capabilities: Allarity expanded its in-house laboratory capabilities to include proteomics and cell line research, complementing its existing gene-expression and DRP services. The expanded capabilities support further investigation of stenoparib’s mechanism of action and broaden the research services available to external partners.

"Our priority is to build the clinical evidence that will guide the next stage of stenoparib development," Mr. Jensen concluded. "As we advance that work, we’re focused on delivering for our first CLIA services customer and building a laboratory business that can generate revenue alongside our clinical programs."

(Press release, Allarity Therapeutics, NOV 13, 2026, View Source [SID1234674771])